** Shares of LTR Pharma LTP.AX fall as much as 8.6% to A$0.96, their lowest level since Aug. 12
** Aussie biotech firm gets binding commitments for A$25 mln private placementat A$0.92/shr, a 12.4% discount to last close
** Says funds to speed development, commercialisation of its SPONTAN nasal spray treatment for erectile dysfunction
** Trading vol of 915,000+ shares tops 30-day avg of ~632,000
** Stock has now surged ~190% YTD
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.